BioSpace News Archive

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Fosaprepitant for Injection and Fulvestrant Injection in the United States.

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced that more than three million ICLs have been sold globally.

Natera, Inc. announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease -guided adjuvant treatment in stage II colorectal cancer patients.

Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.

On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as “chipscreen biosciences”, stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024.

Intellia Therapeutics, Inc. today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001.

Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, announces it has raised an additional £3.7 million in funding.

Selvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio.

CytoMed Therapeutics Limited has obtained board approval to launch, subject to certain terms and conditions, a pilot program to isolate and cryo-store peripheral blood mononuclear cells for and as a reward to loyal shareholders of CytoMed on a complimentary basis.